Search

Search Constraints

You searched for: Author/Creator Di Veroli, Ambra

Search Results

1. Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the "Ph1‐negative Myeloproliferative Neoplasms Latium Group". (16th June 2020)

2. Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN. Issue 8 (August 2015)

3. Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN. Issue 8 (August 2015)

4. Bosutinib in the real‐life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine‐kinase inhibitors. Issue 3 (13th March 2021)

5. CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia. Issue 4 (21st March 2022)

6. Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase. (18th September 2015)

7. Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX‐IOL study. (8th February 2022)

8. Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?. (January 2019)

9. Genetic analysis of erythrocytosis reveals possible causative and modifier gene mutations. (23rd April 2019)

10. High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia. Issue 156 (August 2017)